1-3 of 3
Peggy Ford
Close
Sort by
Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD
Journal: Blood
Blood (2008) 112 (11): 3051.
https://doi.org/10.1182/blood.V112.11.3051.3051
Published: 2008
Journal Articles

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Anne Beaven, MD, Thomas C. Shea, MD, Dominic T Moore, PhD, Tatyana Feldman, MD, Anastasia Ivanova, PhD, Madlyn Ferraro, RN, OCN, CCRC, Peggy Ford, RN, Judy Smith, RN, Andre Goy, MD
Journal: Blood
Blood (2008) 112 (11): 4944.
https://doi.org/10.1182/blood.V112.11.4944.4944
Published: 2008
Journal Articles

A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

Andre Goy, MD, Peggy Ford, Tatyana Feldman, MD, Andrew Pecora, Stuart Goldberg, MD, Michele Donato, David Siegel, David Panush, Mark S. Berger, MD
Journal: Blood
Blood (2007) 110 (11): 2569.
https://doi.org/10.1182/blood.V110.11.2569.2569
Published: 2007